3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 12 areas
0
News (30d)
Quiet
Amarillo Biosciences, Inc. is a company with 3 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Behcet disease | Natural human lymphoblastoid interferon-alpha | Des.TrialAppr. |
| acquired polycythemia vera | natural human lymphoblastoid interferon-alpha | Des.TrialAppr. |
| anogenital human papillomavirus infection | Natural human lymphoblastoid interferon-alpha | Des.TrialAppr. |
| common wart | Natural human lymphoblastoid interferon-alpha | Des.TrialAppr. |
| human papillomavirus-related squamous cell carcinoma | Natural human lymphoblastoid interferon-alpha | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
4
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
4
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio